Cyrano Therapeutics has started enrolment in the Phase II FLAVOR trial of CYR-064, a new soft-mist nasal spray product candidate, for post-viral smell loss (hyposmia).
The placebo-controlled, multi-dose study will evaluate the local nasal safety, effectiveness and tolerability of CYR-064 against placebo in post-viral hyposmia treatment for six months.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Cyrano plans to enrol around 150 patients in the randomised and double-blinded study.
The multi-institutional prospective trial is being carried out at 15 US clinical sites.
Cyrano Therapeutics president and CEO Rick Geoffrion said: “We are excited to announce a significant milestone in our commitment to advancing medical science and improving the lives of those affected by post-viral smell loss.
“With the enrolment of the first patients in our Phase II trial of CYR-064, we take a giant step forward in addressing a pressing health concern.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“In a world where post-viral smell loss continues to affect an ever-growing number of individuals, we’re dedicated to pioneering solutions that make a difference.”
Post-viral hyposmia is a growing and serious chronic sensory condition, with no approved drug treatment available at present.
Hyposmia in older individuals is linked to increased cognitive impairment and mortality risk.
Before the Covid-19 pandemic, approximately eight million people in Europe and the US experienced long-term post-viral hyposmia.
This pandemic has led to a significant rise in the number of people experiencing long-term post-viral hyposmia.
